DekmarTrades
Stock Day Trader & Educator, Live Trading
Kodiak Sciences has room to run after positive Phase III results, with $82.50 as the next major target. Zenkuda and tabirafusp-ted met their primary endpoints in the pivotal DAYBREAK trial in wet AMD, and Zenkuda showed a potential new standard-of-care profile, with most patients on a 24-week dosing interval under strict real-world retreatment criteria. Positive Phase III data is among the best news a company can release. x.com x.comÂ
4D Molecular Therapeutics has a worthless pipeline, aimed at AMD treatments that roughly 50 other companies are also pursuing. x.comÂ
Kodiak Sciences looks very extended after a 150% jump on its data release, as the stock is baking in full success that will take time to deliver. It will also need to raise capital. This is a low-conviction short, serving as a hedge for other high-conviction longs. x.com x.comÂ
